VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Nurix Therapeutics Executive Compensation (FY25)

NRIX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Arthur Sands
Latest say-on-pay support
=
May 15, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Nurix Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): May 15, 2026
7 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Nurix Therapeutics brief$500Get the executive brief
Velarion Intel, one year, every company
235 figures on this page: 230 cited to the filing that reported them, 5 calculated from figures it prints. See the citations

More on Nurix Therapeutics

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Arthur Sands: $5,812,862 → $6,374,138 (9.7% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Nurix Therapeutics' chief executive and what were they paid?
Total compensation for Arthur Sands, President, Chief Executive Officer and Director, came to $6,374,138 in fiscal 2025. Sands' total moved 9.7% higher from the $5,812,862 reported for fiscal 2024.
What was Nurix Therapeutics' say-on-pay result?
Shareholders supported the say-on-pay proposal with 91.3% of votes cast for or against in favor at the meeting held May 15, 2026 for fiscal 2025.
Which companies are in Nurix Therapeutics' peer group?
The disclosed peer group includes Arcellx Inc., Arcus Biosciences, Inc., Arvinas, Inc., C4 Therapeutics, Inc. and Celldex Therapeutics, Inc., among others.
What is Nurix Therapeutics' chief executive pay ratio?
The company reported a chief executive pay ratio of 23:1 for fiscal 2025, against median employee compensation of $274,252.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Arthur Sands
President, Chief Executive Officer and Director
◇——◇◇—◇◇
Hans van Houte
Chief Financial Officer
◇—◇◇◇—◇— not reconciled
Gwenn Hansen
Chief Scientific Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Arthur Sands
President, Chief Executive Officer and Director
◇——◇◇—◇◇
Gwenn Hansen
Chief Scientific Officer
◇—◇◇◇—◇◇
Hans van Houte
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Arthur Sands
President, Chief Executive Officer and Director
◇——◇◇—◇◇
Gwenn Hansen
Chief Scientific Officer
◇—◇◇◇—◇◇
Christine Ring
Chief Legal Officer and Chief Compliance Officer
◇—◇◇◇—◇◇
Hans van Houte
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Arthur Sands
President, Chief Executive Officer and Director
◇——◇◇—◇◇
Gwenn Hansen
Chief Scientific Officer
◇—◇◇◇—◇◇
Hans van Houte
Chief Financial Officer
◇—◇◇◇—◇◇
Christine Ring
Chief Legal Officer and Chief Compliance Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Arthur T. SandsOPTION◇——◇—◇◇
Christine RingRSU◇——◇——◇
Christine RingOPTION◇——◇—◇◇
Gwenn M. HansenOPTION◇——◇—◇◇
Gwenn M. HansenRSU◇——◇——◇
Gwenn M. HansenRSU◇——◇——◇
Hans van HouteRSU◇——◇——◇
Hans van HouteOPTION◇——◇—◇◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Arthur SandsOption◇—◇February 10, 2035
Option◇—◇February 12, 2034
Option◇—◇August 8, 2032
Option◇—◇February 13, 2033
Option◇—◇January 19, 2032
Christine RingOption◇—◇February 12, 2034
Option◇—◇February 10, 2035
RSU◇◇——
RSU◇◇——
Option◇—◇August 8, 2032
Option◇—◇February 13, 2033
RSU◇◇——
Option◇—◇January 18, 2032
RSU◇◇——
Gwenn HansenOption◇—◇February 12, 2034
Option◇—◇February 10, 2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇August 8, 2032
Option◇—◇February 13, 2033
Option◇—◇January 3, 2032
RSU◇◇——
RSU◇◇——
Hans van HouteOption◇—◇February 12, 2034
Option◇—◇February 10, 2035
RSU◇◇——
Option◇—◇August 8, 2032
RSU◇◇——
Option◇—◇February 13, 2033
Option◇—◇January 18, 2032
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Roy D. Baynes
◇—◇———◇
Roger Dansey
◇—◇———◇
Julia P. Gregory
◇—◇——◇◇
Paul M. Silva
◇—◇———◇
Judith A. Reinsdorf
◇—◇———◇
David L. Lacey
◇—◇———◇
Edward C. Saltzman
◇—◇——◇◇
Anil Kapur
◇—◇———◇
Lori A. Kunkel
◇—◇———◇
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Arcellx Inc. ACLX
  • Arcus Biosciences, Inc. RCUS
  • Arvinas, Inc. ARVN
  • C4 Therapeutics, Inc. CCCC
  • Celldex Therapeutics, Inc. CLDX
  • Cullinan Therapeutics, Inc. CGEM
  • Erasca, Inc. ERAS
  • IDEAYA Biosciences, Inc. IDYA
  • IGM Biosciences Inc. IGMS
  • Intellia Therapeutics Inc. NTLA
  • Iteos Therapeutics Inc. ITOS
  • Kura Oncology Inc. KURA
  • Kymera Therapeutics Inc. KYMR
  • Monte Rosa Therapeutics Inc. GLUE
  • ORIC Pharmaceuticals Inc. ORIC
  • Recursion Pharmaceuticals Inc. RXRX
  • Relay Therapeutics Inc. RLAY
  • Replimune Group Inc. REPL
  • Sutro Biopharma Inc. STRO
  • Tango Therapeutics Inc. TNGX
  • Zentalis Pharmaceuticals Inc. ZNTL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 15, 2026=◇◇◇
2024May 19, 2025=◇◇◇
2023May 20, 2024=◇◇◇
2022May 4, 2023=◇◇◇
2021May 5, 2022=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Arthur Sands (President, Chief Executive Officer and Director), FY2025 total compensation $6,374,138 (base salary $674,584) [exec_comp, SEC accession 0001140361-26-011492, filed 2026-03-27]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when Nurix Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Nurix Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Nurix Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Nurix Therapeutics' disclosed peer group is defensible, who names Nurix Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
235 figures on this page: 230 cited to the filing that reported them, 5 calculated from figures it prints.
230 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001549595-26-000028
    Proposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company s Named Executive Officers
  2. 0001140361-26-011492
    EXECUTIVE COMPENSATION TABLES · Grants of Plan-Based Awards · Non-Employee Director Compensation · PAY RATIO DISCLOSURE
  3. 0001549595-25-000067
    Proposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company s Named Executive Officers
  4. 0001549595-24-000073
    Proposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company s Named Executive Officers
  5. 0001549595-23-000034
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001140361-23-013573
    Summary Compensation Table
  7. 0001193125-22-142944
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Nurix Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/NRIX (accessed 2026).
Short form: data: Velarion

The paid brief for Nurix Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Nurix Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Nurix Therapeutics discloses

The companies named in NRIX's own disclosed peer group.

Arcellx Inc.Arcus Biosciences, Inc.Arvinas, Inc.C4 Therapeutics, Inc.Celldex Therapeutics, Inc.Cullinan Therapeutics, Inc.Erasca, Inc.IDEAYA Biosciences, Inc.IGM Biosciences Inc.Intellia Therapeutics Inc.Iteos Therapeutics Inc.Kura Oncology Inc.Kymera Therapeutics Inc.Monte Rosa Therapeutics Inc.ORIC Pharmaceuticals Inc.Recursion Pharmaceuticals Inc.Relay Therapeutics Inc.Replimune Group Inc.Sutro Biopharma Inc.Tango Therapeutics Inc.Zentalis Pharmaceuticals Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy